HyClone™ cell culture media, sera, and process liquids, now part of GE Healthcare – GE Healthcare Life Sciences

Commenting on the acquisition, Kieran Murphy, President and CEO of GE Healthcare’s Life Sciences business says, “GE Healthcare has built a world-class set of technologies for the life science sector, and these new businesses will enhance our current offerings. As well as providing us with new tools for drug discovery and biomedical research, our customers will benefit straight away from an expanded range of start-to-finish solutions that will help improve product yields and reduce time to market. Through this acquisition, we expand our production capabilities of cell culture media and sera in Asia, the Americas, and Europe, enabling us to offer the biopharmaceutical industry greater confidence in security of supply of key parts of their production processes”.

With the HyClone capabilities, GE Healthcare delivers validated solutions from life science research to biopharmaceutical manufacturing. We offer an extensive line of classical and specialty media, sera, reagents, and supplements for a wide variety of cell culture applications. With manufacturing sites across the world— including the new manufacturing facility for powder media in Singapore—we can provide efficient solutions tailored to your needs.

Learn more about HyClone cell culture media, sera, and process liquids at www. gelifesciences.com/hyclone

---

---